FDA Requests Minor Labeling Changes for NRx’s Preservative-Free Ketamine

  • FDA issued a Discipline Review Letter for NRx’s Preservative-Free Ketamine, requesting minor labeling changes.
  • All requested changes classified as minor, with a November 10, 2026, GDUFA goal date for review completion.
  • NRx is finalizing manufacturing Process Validation Runs to meet product launch requirements.
  • Company aims to address domestic ketamine shortages with US-manufactured preservative-free formulation.

NRx’s preservative-free ketamine addresses critical supply chain gaps in the US healthcare system, aligning with broader trends of reshoring pharmaceutical manufacturing. The FDA’s minor labeling requests suggest a smooth regulatory path, but execution risks remain in scaling production. Success could position NRx as a key player in neuroplastic therapies for depression and PTSD.

Regulatory Approval
Whether NRx can meet the November 10, 2026, GDUFA goal date for final FDA approval.
Market Impact
How successful US manufacturing of preservative-free ketamine will affect domestic supply shortages.
Execution Risk
The pace at which NRx completes final manufacturing validation runs for product launch.